Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRI 50c in chronic haemodialysis patients
2005-000177-22Phase 2Completed
- Sponsor
- Trigen
- Start
- Jun 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flovagatran in chronic kidney disease (CKD), sponsored by Trigen. Primary endpoints: Safety and tolerability of TRI 50c during haemodialysis, Pharmacodynamic efficacy of TRI 50c and 1 more. Started Jun 2005; status: completed.
02
Drugs
flovagatran
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-000177-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000177-22.